RT Journal Article
SR Electronic
T1 COVID-19 severity in asthma patients: A multi-center matched cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.02.20205724
DO 10.1101/2020.10.02.20205724
A1 Lacey B. Robinson
A1 Liqin Wang
A1 Xiaoqing Fu
A1 Zachary S. Wallace
A1 Aidan A. Long
A1 Yuqing Zhang
A1 Carlos A. Camargo, Jr
A1 Kimberly G. Blumenthal
YR 2020
UL http://medrxiv.org/content/early/2020/10/05/2020.10.02.20205724.abstract
AB Objective The evidence pertaining to the effects of asthma on Coronavirus disease 2019 outcomes has been unclear. To improve our understanding of the clinically important association of asthma and Coronavirus disease 2019.Methods A matched cohort study was performed using data from the Mass General Brigham Health Care System (Boston, MA). Adult (age ≥ 18 years) patients with confirmed Coronavirus disease 2019 and without chronic obstructive pulmonary disease, cystic fibrosis, or interstitial lung disease between March 4, 2020 and July 2, 2020 were analyzed. Up to 5 non-asthma comparators were matched to each asthma patient based on age (within 5 years), sex, and date of positive test (within 7 days). The primary outcomes were hospitalization, mechanical ventilation, and death, using multivariable Cox-proportional hazards models accounting for competing risk of death, when appropriate. Patients were followed for these outcomes from diagnosis of Coronavirus disease 2019 until July 2, 2020.Results Among 562 asthma patients, 199 (21%) were hospitalized, 15 (3%) received mechanical ventilation, and 7 (1%) died. Among the 2686 matched comparators, 487 (18%) were hospitalized, 107 (4%) received mechanical ventilation, and 69 (3%) died. The adjusted Hazard Ratios among asthma patients were 0.99 (95% Confidence Internal 0.80, 1.22) for hospitalization, 0.69 (95% Confidence Internal 0.36, 1.29) for mechanical ventilation, and 0.30 (95% Confidence Internal 0.11, 0.80) for death.Conclusions In this matched cohort study from a large Boston-based healthcare system, asthma was associated with comparable risk of hospitalization and mechanical ventilation but a lower risk of mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo specific funding was received for this project. Dr. Camargo is supported, in part, by grant R01AI127507 from the National Institutes of Health. Dr. Blumenthal is supported by National Institutes of Health K01AI125631, the American Academy of Allergy Asthma and Immunology Foundation (AAAAI), and the Massachusetts General Hospital Claflin Distinguished Scholars Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, AAAAI Foundation, nor the MGH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed by the Partners Human Research Committee and determined to be exempt/non-human subjects research (Protocol 2020P000833).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are from Mass General Brigham and are not publicly available.ACE2angiotensin-converting enzyme 2CFcystic fibrosisCOPDchronic obstructive pulmonary diseaseCOVID-19Coronavirus disease 2019HRhazard ratioICD-10-CMInternational Classification of Diseases, Tenth Revision, Clinical ModificationILDinterstitial lung diseaseMERSMiddle eastern respiratory syndromeMGBMass General BrighamPCRpolymerase chain reactionSARSsevere acute respiratory syndromeSARS-CoV-2severe acute respiratory syndrome coronavirus 2USUnited States